
QuidelOrtho Corporation
NASDAQ•QDEL
CEO: Mr. Joseph M. Busky CPA
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1991-02-01
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
連絡先情報
時価総額
$1.57B
PER (TTM)
-1.4
67
配当利回り
--
52週高値
$42.50
52週安値
$19.50
52週レンジ
順位39Top 39.1%
4.2
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$723.60M+0.00%
直近4四半期の推移
EPS
-$1.95+0.00%
直近4四半期の推移
フリーCF
$0.00+0.00%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Net Loss Significantly Narrows Nine month net loss reduced to $(1,001.1)M$ from $(1,873.6)M$ previous period, reflecting lower charges recognized.
Goodwill Impairment Declines Goodwill impairment charge dropped to $700.7M$ for nine months, compared to $1.74B$ recognized last year.
Core Labs Revenue Rises Labs segment revenue increased 5% to $1,116.5M$ for nine months, driven by reagents and consumables growth.
Working Capital Improves Working capital reached $598.8M$ as of September 28, 2025, significantly increasing from $220.1M$ year-end.
リスク要因
Total Revenue Decreases Nine month total revenues fell 3% to $2,006.6M$, impacted by respiratory product variability and pricing pressures.
Donor Screening Portfolio Exits Donor Screening revenue fell 57% to $40.8M$ (9M) due to planned wind-down of U.S. portfolio operations.
Operating Cash Flow Negative Net cash used for operating activities totaled $(26.7)M$ for nine months, contrasting prior period cash generation.
Increased Restructuring Costs Restructuring and integration charges rose to $234.6M$ (9M) due to Optimization Plan and Savanna Exit costs.
見通し
Optimization Plan Cost Savings Optimization Plan targets $50M$ net cost savings by 2027 through facility rationalization and procurement efforts.
Strategic Focus Shifts Company refocusing Molecular Diagnostics, planning Savanna Exit completion by H1 2027, intending to acquire LEX Diagnostics.
Short-Term Liquidity Secure Cash and Revolving Credit Facility sufficient to fund near-term capital and operating needs for at least 12 months.
Growing Reagent Rentals Increasing reagent rental placements to lower customer upfront costs, growing installed base and recurring revenue streams.
同業比較
売上高 (TTM)
XRAY$3.62B
QDEL$2.73B
$1.50B
粗利益率 (最新四半期)
VRDN100.0%
RCUS92.3%
QURE89.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| TWST | $3.24B | -42.2 | -16.6% | 28.8% |
| EWTX | $3.18B | -20.2 | -30.9% | 0.7% |
| NHC | $2.56B | 25.2 | 10.0% | 8.1% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.5%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月5日
EPS:-
|売上高:-
財務レポート
財務データ
ニュース
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月28日|提出日: 2025年11月6日|売上高: $699.90M-3.7%|EPS: $-10.78+3493.3%予想を下回るForm 10-Q - Q2 2025
会計期末: 2025年6月29日|提出日: 2025年8月6日|売上高: $615.10M-3.4%|EPS: $-3.77+71.4%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年3月30日|提出日: 2025年5月8日|売上高: $692.80M-2.6%|EPS: $-0.19-99.3%予想を下回るForm 10-K - FY 2024
会計期末: 2024年12月29日|提出日: 2025年2月27日|売上高: $2.78B-7.2%|EPS: $-30.54-20260.0%予想を下回るForm 10-Q - Q3 2024
会計期末: 2024年9月29日|提出日: 2024年11月8日|売上高: $727.10M-2.3%|EPS: $-0.30+57.9%予想を下回るForm 10-K/A - FY 2023
会計期末: 2023年12月31日|提出日: 2024年8月1日|売上高: $3.00B-8.2%|EPS: $-0.15-101.6%予想を下回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月1日|売上高: $637.00M-4.2%|EPS: $-2.20+175.0%予想を下回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月9日|売上高: $711.00M-16.0%|EPS: $-25.50-3593.2%予想を下回る